China TCM (570.HK) Privatization Update - Investors May Need to Prepare for a Longer Wait
Xinyao has highlighted this Insight as a Top Pick
934 Views05 Jun 2024 08:55
China TCM's privatization process is complex and would take more time. So, delays are expected. But it's still a good investment opportunity for idle funds considering the corresponding risks/returns
What is covered in the Full Insight:
- Introduction
- Approval Process
- Arbitrage Opportunity
- Historical Analysis
- Investor Considerations
Boomeranged on Thu, 27 Jun 2024 16:21
According to IR, if there's no update, it's expected to announce the progress of privatization in mid next month. The announcement is arranged by the Offeror. Today, the mkt acted as if the deal is dead: HK$3.5/share basically reflects a failed deal.If it does fail, sentiment will push the stock below HK$3/share, but will bounce back due to solid fundamentals.Pls remember, the Offer is still there
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- Ascentage Pharma (6855.HK) Signs $1.3B Deal with Takeda - Finally on the Right Path17 Jun 2024
- CPMC Holdings (906.HK) - ORG Can't Afford to Lose, But Baosteel Is a Step Ahead11 Jun 2024
- Asia Cement China (743.HK) Privatization- There May Be "Surprises" Despite Disappointing Offer Price10 Jun 2024
- China TCM (570.HK) Privatization Update - Investors May Need to Prepare for a Longer Wait05 Jun 2024
- L'Occitane (973.HK) Privatization - The Offer Price Is Good Enough07 May 2024
- China TCM (570.HK) Update - Despite Doubts, This Privatization Seems “Mandatory”06 May 2024
- Sciclone Pharmaceuticals (6600.HK) - The Privatization Offers a Good Exit Opportunity02 Apr 2024
x